180 Life Sciences Corp. (NASDAQ:ATNF) Sees Large Growth in Short Interest

Posted by Editorial Team on Mar 17th, 2025

180 Life Sciences Corp. (NASDAQ:ATNF – Get Free Report) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 33,500 shares, an increase of 29.3% from the February 13th total of 25,900 shares. Based on an average trading volume of 410,200 shares, the days-to-cover ratio is currently 0.1 days. Currently, 2.4% of the company’s stock are short sold.

180 Life Sciences Stock Performance

180 Life Sciences stock opened at $1.07 on Monday. 180 Life Sciences has a 12 month low of $0.98 and a 12 month high of $17.75. The company’s fifty day simple moving average is $1.37 and its 200-day simple moving average is $2.04.

Institutional Investors Weigh In On 180 Life Sciences

A hedge fund recently bought a new stake in 180 Life Sciences stock. Rathbones Group PLC acquired a new position in 180 Life Sciences Corp. (NASDAQ:ATNF – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 69,995 shares of the company’s stock, valued at approximately $127,000. Rathbones Group PLC owned about 2.20% of 180 Life Sciences at the end of the most recent quarter. 4.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of 180 Life Sciences in a research report on Friday, March 7th.

Check Out Our Latest Report on ATNF

About 180 Life Sciences

(Get Free Report)

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.